- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01597349
Antitussive Effects of FP01 Lozenges in Subjects With Cough Due to Upper Respiratory Tract Infection
January 27, 2014 updated by: Avalo Therapeutics, Inc.
An Exploratory, Randomized, Placebo Controlled, Double Blind, Parallel Arm Dose Ranging Study to Determine the Antitussive Effects of FP01 Lozenges in Subjects With Cough Due to Upper Respiratory Tract Infection
The purpose of this research study is to learn how effective and safe FP01 lozenges are when given to subjects with a cough due to an upper respiratory tract infection.
The study will include subjects who have an upper respiratory tract infection, with a cough of less than six weeks duration.
Study Overview
Study Type
Interventional
Enrollment (Actual)
208
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
gastroesophageal INCLUSION CRITERIA
Subject must state that they have had a "cold" for < 14 days. A "cold" is defined as:
- Moderate or severe rhinorrhea (i.e., using 2 or more tissues per hour for any 1 hour within 12 hours preceding study screening AND
- At least one other respiratory symptom (cough, pharyngeal symptoms [sore throat], nasal congestion of moderate or severe intensity, headache, etc.)
- Subject must exceed a cough severity threshold (VAS) during screening visit (Cough Severity VAS score ≥ 40 mm).
- Subjects who recall that their average number of days with cough during their usual cold history is 3 or greater (URTI cough history > 3).
- Subjects who do not smoke or use nicotine or nicotine containing products. Ex-smokers/ex-tobacco users must have stopped using tobacco products for at least 6 months prior to study screening.
- Female subjects should be either post-menopausal (amenorrhea for at least 12 consecutive months), surgically sterile, or women of child-bearing potential (WOCP) with a negative serum beta human chorionic gonadotropin (HCG) pregnancy test prior to entering the study and who are using or agree to use an acceptable method of contraception as determined by the Investigator. Acceptable contraceptives include abstinence OR intrauterine devices (IUDs), hormonal contraceptives (oral, depot, patch or injectable) for ≥ three months prior to screening OR use of double barrier methods such as condoms or diaphragms with spermicidal gel or foam.
- Subject must sign an Institutional Review Board approved informed consent and agree to complete required clinic visits.
EXCLUSION CRITERIA
- Subject who are using antibiotics at study screening or for whom antibiotics are currently indicated as determined by the Investigator.
- History of cough of greater than 6 weeks in duration.
- History of any chronic pulmonary disease including tuberculosis, lung cancer, chronic bronchitis or emphysema
- History of pneumonia, influenza or whooping cough within the past 30 days.
- History of asthma that required any treatment within 2 weeks of study
- T > 38.5oC with no history of anti-pyretic medication for > 24 hours from screening visit
- History of inhalational exposure (chemical, smoke, water, etc.) within the past 6 months
- Chest X-ray suggestive of granulomatous disease, malignancy, COPD, bronchiectasis, pneumonia, pleural processes or other underlying pulmonary disease
- Active, concurrent concomitant disease which might limit the ability of the subject to participate in the study as determined by the Investigator (i.e., diabetes mellitus, congestive heart failure, unstable angina, etc.)
- Prior or current renal disease; calculated creatinine clearance < 30 ml/min (calculated ClCr < 30)
- Known immune deficiency condition
- Use of opioids or anticonvulsants within 3 days of study screening.
- Known hypersensitivity to memantine or lozenge excipients.
- Current oral lesions or abnormal findings on buccal examination done at study screening.
- History of oropharyngeal or gastroesophageal carcinoma, or gastro/esophageal/duodenal resection.
- Subject has clinically significant abnormal laboratory test results at the screening visit. (Subject may be enrolled by exception, as determined by the Principal Investigator and consented by Cerecor's Medical Monitor.)
- Any clinically significant finding on the ECG done at the screening visit, as determined by the investigator. (Subject may be enrolled by exception, as determined by the Principal Investigator and consented by Cerecor's Medical Monitor).
- Female subjects who are pregnant, breast feeding or sexually active without contraception.
- Subject has donated blood or plasma within the last 45 days.
- Subject has history of alcohol or drug abuse in past 2 years.
- Subject has a positive drug screen.
- Subject has a positive HIV, Hepatitis B or Hepatitis C test.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
Lozenge 3 times per day, low dose, high dose, or placebo for 48 hours.
|
Experimental: FP01 High dose
|
Lozenge 3 times per day, low dose, high dose, or placebo for 48 hours.
|
Experimental: FP01 Low dose
|
Lozenge 3 times per day, low dose, high dose, or placebo for 48 hours.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in cough count, active vs placebo treatment period
Time Frame: Daily for 48 hours
|
Daily for 48 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety
Time Frame: Daily over 3 days
|
The evaluation of treatment safety will take into account the recorded adverse events, vital signs, clinical and laboratory assessments and the buccal cavity examination
|
Daily over 3 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2012
Primary Completion (Actual)
September 1, 2012
Study Completion (Actual)
September 1, 2012
Study Registration Dates
First Submitted
May 9, 2012
First Submitted That Met QC Criteria
May 11, 2012
First Posted (Estimate)
May 14, 2012
Study Record Updates
Last Update Posted (Estimate)
February 28, 2014
Last Update Submitted That Met QC Criteria
January 27, 2014
Last Verified
January 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CLIN01-002-A
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Cough
-
PhytoHealth CorporationCompleted
-
Engelhard Arzneimittel GmbH & Co.KGCompleted
-
Universidade Federal de PernambucoUnknown
-
Merck Sharp & Dohme LLCTerminated
-
Trevi TherapeuticsRecruitingRefractory Chronic CoughCanada, United Kingdom
-
Respivant Sciences GmbHRespivant Sciences Inc.TerminatedChronic Cough | IPF | Persistent Cough in IPFUnited States, United Kingdom, Netherlands, Australia, Belgium, New Zealand, Turkey, Italy, Germany, Czechia, Canada
-
The First Affiliated Hospital of Zhejiang Chinese...Completed
-
ILiAD BiotechnologiesCompletedPertussis/Whooping Cough | Bordetella Pertussis, Whooping CoughUnited Kingdom
-
KK Women's and Children's HospitalSingapore University of Technology and DesignUnknownCough | URTI | Cough Variant Asthma | Cough; Bronchial, With Grippe or InfluenzaSingapore
-
The First Affiliated Hospital of Guangzhou Medical...UnknownEosinophilic Bronchitis | Cough Variant AsthmaChina
Clinical Trials on FP01
-
Avalo Therapeutics, Inc.Completed
-
Avalo Therapeutics, Inc.CompletedChronic Refractory CoughUnited States